The use of non-steroidal anti-inflammatory drugs in patients with cardiovascular diseases – what do we know today? Review article
Article Sidebar
Main Article Content
Abstract
Non-steroidal anti-inflammatory drugs are in common use, also in patients with cardiovascular diseases. Overdosing or inappropriate chose of one of NSAID leads to serious complications including cardiovascular. NSAID reduce effectiveness of hypotensive drugs, may cause renal failure, increase risk of cardiovascular incidence, can interact with statins, beta-adrenolytics and diuretics. When use with aspirin some may reduce its antiplatelet effects.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Woroń J., Filipczak-Bryniarska I., Wordliczek J.: Nieopioidowe leki przeciwbólowe w farmakoterapii bólu. W: Kompedium leczenia bólu. Pod red. Małgorzaty Malec-Milewskiej i Jarosława Woronia. Wyd. 1. Medical Education, Warszawa 2012.
3. Burke A., Smyth E., FitzGerald G.A.: Leki przeciwbólowe-przeciwgorączkowe; farmakoterapia dny moczanowej. W: Farmakoterapia Goodmana & Gilmana. Bruton L.L., Lazo J.S., Parker K.L. Wyd. I. Czelej, Lublin 2007.
4. Lisowska B., Rell-Bakalarska M., Rutkowska-Sak L.: Niesteroidowe leki przeciwzapalne – blaski i cienie. Reumatologia 2006, 44, 2: 106-111.
5. Tamblyn R., Berkson L., Dauphinee W.D. et al.: Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann. Intern. Med. 1997, 127: 429-38.
6. Wolfe M.M., Lichtenstein D.R., Singh G.: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 1999, 340: 1888-99.
7. Graham D.Y., Opekun A.R., Willingham F.F. et al.: Visible small-intestinal mucosal injury in chronic NSAID users. Clin. Gastroenterol. Hepatol. 2005, 3: 55-9.
8. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). European Heart Journal [online: doi:10.1093/eurheartj/ehs092].
9. Capone M.L., Tacconelli S., Sciulli M.G. et al.: Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and lowdose aspirin in healthy subjects. Circulation 2004, 109: 1468-1471.
10. Graham D.J.: COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk – The Seduction of Common Sense. JAMA. published online 2006 Sep 12 [online: doi: 10.1001/jama.296.13.jed60058].
11. Bresalier R.S., Sandler R.S., Quan H. et al., Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [published correction appears in N. Engl. J. Med. 2006, 355: 221]. N. Engl. J. Med. 2005, 352: 1092-1102.
12.McGettigan P., Henry D.: Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. 2011, PLoS Med 8(9): e1001098 [online: doi: 10.1371/journal.pmed.1001098].
13. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S. et al.: Cyclo-oxygenase inhibitors and the anti-platelet effect of aspirin. N. Engl. J. Med. 2001, 345: 1809-1817.
14. Meek I.L., Vonkeman H.E. Kasemier J. et al.: Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur. J. Clin. Pharmacol. [online: doi: 10.1007/s00228-012-1370-y].
15. Awa K., Satoh H., Hor S., Sawada Y.: Prediction of timedependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model. J. Clin. Pharm. Ther. 2012, 37: 469-474.
16. Anzellotti P., Capone M.L., Jeyam A. et al.: Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum. 2011, 63(3): 850-859.